Examples of using P-values in English and their translations into Hungarian
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Programming
-
Official/political
-
Computer
A P-values by logrank test.
(2007) such question might center on whether they computed their p-values correctly.
Reported p-values are two-tailed.
Text insets give Pearson's correlation coefficients and associated p-values.
P-values compared to pamidronate.
All reported P-values are two-sided.
P-values were not corrected for multiple testing.
On adjusting P-values for multiplicity.
P-values are all adjusted p-values for multiplicity.
For all other endpoints, the p-values correspond to a test of differences in hazard rates.
P-values for olanzapine and quetiapine XR vs. placebo were unadjusted.
There was no evidence of period,sequence/carry-over effects in the ASCEND-PD study(p-values all> 0.10).
Pairwise comparison p-values:*= p< 0.05 for comparisons of LIFMIOR vs.
As the primary endpoint(change in 6MWD from baseline to Week 48) did not reach statistical significance(p≤0.05),all other p-values should be considered nominal.
Pairwise comparison p-values:*= p< 0.05 for comparisons of etanercept vs.
P-values represent each infliximab treatment group vs. AZA monotherapy.
Median values from Kaplan-Meier analysis; HR and p-values from Cox regression models adjusting for important prognostic factors.
P-values for comparison versus pre-Tx values were computed using paired t-tests.
Remission is defined as DAS< 1.6 Pairwise comparison p-values:†= p< 0.05 for comparisons of Enbrel+ methotrexate vs methotrexate and= p< 0.05 for comparisons of Enbrel+ methotrexate vs Enbrel.
HR and p-values from Cox regression models adjusting for important prognostic factors.
Tho 100 All p-values are pairwise comparisons of proportions for Trudexa versus placebo* p< 0.001**.
Other studies: p-values compared each efalizumab group with placebo using Fisher's exact test within each study. p< 0.001.
Wald p-values are quoted for the comparison of treatments using logistic regression with factors for treatment and region.
The p-values for ORR and Global Health Status/Quality of Life(QoL) scores are descriptive based on the pre-specified multiplicity adjustment plan.
Pairwise comparison p-values:†= p< 0.05 for comparisons of Enbrel+ methotrexate vs. methotrexate and= p< 0.05 for comparisons of Enbrel+ methotrexate vs.
Pairwise comparison p-values:†= p< 0.05 for comparisons of etanercept+ methotrexate vs. methotrexate and Φ= p< 0.05 for comparisons of etanercept+ methotrexate vs. etanercept.
IMP24011: p-values compared efalizumab with placebo using logistic regression including baseline PASI score, prior treatment for psoriasis and geographical region as covariates.
P-values were derived from comparison for change from baseline within analysis of covariance model with treatment as term and baseline as covariate.
Pairwise comparison p-values:*= p< 0.05 for comparisons of Enbrel vs methotrexate,†= p< 0.05 for comparisons of Enbrel+ methotrexate vs methotrexate and= p< 0.05 for comparisons of Enbrel+ methotrexate vs Enbrel.